These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 34535038)

  • 21. Use of Antivirals in SARS-CoV-2 Infection. Critical Review of the Role of Remdesivir.
    Moreno S; Alcázar B; Dueñas C; González Del Castillo J; Olalla J; Antela A
    Drug Des Devel Ther; 2022; 16():827-841. PubMed ID: 35370401
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Beneficial effect of combinational methylprednisolone and remdesivir in hamster model of SARS-CoV-2 infection.
    Ye ZW; Yuan S; Chan JF; Zhang AJ; Yu CY; Ong CP; Yang D; Chan CC; Tang K; Cao J; Poon VK; Chan CC; Cai JP; Chu H; Yuen KY; Jin DY
    Emerg Microbes Infect; 2021 Dec; 10(1):291-304. PubMed ID: 33538646
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An effective drug against COVID-19: reality or dream?
    Yaghoubi A; Amel Jamehdar S; Movaqar A; Milani N; Soleimanpour S
    Expert Rev Respir Med; 2021 Apr; 15(4):505-518. PubMed ID: 33215942
    [No Abstract]   [Full Text] [Related]  

  • 24. [The praise of uncertainty: a systematic living review to evaluate the efficacy and safety of drug treatments for patients with covid-19.].
    Cruciani F; Amato L; De Crescenzo F; Mitrova Z; Saulle R; Vecchi S; Davoli M
    Recenti Prog Med; 2021 Mar; 112(3):195-206. PubMed ID: 33687358
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interactions Between Remdesivir, Ribavirin, Favipiravir, Galidesivir, Hydroxychloroquine and Chloroquine with Fragment Molecular of the COVID-19 Main Protease with Inhibitor N3 Complex (PDB ID:6LU7) Using Molecular Docking.
    Silva Arouche TD; Reis AF; Martins AY; S Costa JF; Carvalho Junior RN; J C Neto AM
    J Nanosci Nanotechnol; 2020 Dec; 20(12):7311-7323. PubMed ID: 32711596
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Emerging treatment strategies for COVID-19 infection.
    Gavriatopoulou M; Ntanasis-Stathopoulos I; Korompoki E; Fotiou D; Migkou M; Tzanninis IG; Psaltopoulou T; Kastritis E; Terpos E; Dimopoulos MA
    Clin Exp Med; 2021 May; 21(2):167-179. PubMed ID: 33128197
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The therapeutic efficacy of quercetin in combination with antiviral drugs in hospitalized COVID-19 patients: A randomized controlled trial.
    Shohan M; Nashibi R; Mahmoudian-Sani MR; Abolnezhadian F; Ghafourian M; Alavi SM; Sharhani A; Khodadadi A
    Eur J Pharmacol; 2022 Jan; 914():174615. PubMed ID: 34863994
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recent knowledge in favor of remdesivir (GS-5734) as a therapeutic option for the COVID-19 infections.
    Saqrane S; El Mhammedi MA; Lahrich S; Laghrib F; El Bouabi Y; Farahi A; Bakasse M
    J Infect Public Health; 2021 May; 14(5):655-660. PubMed ID: 33857725
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical Trials of Repurposed Antivirals for SARS-CoV-2.
    Martinez MA
    Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32631826
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Favipiravir use in children with COVID-19 and acute kidney injury: is it safe?
    Ozsurekci Y; Oygar PD; Gürlevik SL; Kesici S; Ozen S; Kurt Sukur ED; Gülhan B; Topaloglu R; Bayrakci B; Cengiz AB
    Pediatr Nephrol; 2021 Nov; 36(11):3771-3776. PubMed ID: 34021797
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Remdesivir as a broad-spectrum antiviral drug against COVID-19.
    Hong YN; Xu J; Sasa GBK; Zhou KX; Ding XF
    Eur Rev Med Pharmacol Sci; 2021 Jan; 25(1):541-548. PubMed ID: 33506946
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Remdesivir and Its Combination With Repurposed Drugs as COVID-19 Therapeutics.
    Chatterjee B; Thakur SS
    Front Immunol; 2022; 13():830990. PubMed ID: 35634324
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A complementary critical appraisal on systematic reviews regarding the most efficient therapeutic strategies for the current COVID-19 (SARS-CoV-2) pandemic.
    Kheirabadi D; Haddad F; Mousavi-Roknabadi RS; Rezaeisadrabadi M; Dehghan H; Fazlzadeh A
    J Med Virol; 2021 May; 93(5):2705-2721. PubMed ID: 33463727
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nirmatrelvir-remdesivir association for non-hospitalized adults with COVID-19, point of view.
    Ferrara F; Zovi A; Trama U; Vitiello A
    Inflammopharmacology; 2022 Oct; 30(5):1927-1931. PubMed ID: 35980509
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency.
    Gordon CJ; Tchesnokov EP; Woolner E; Perry JK; Feng JY; Porter DP; Götte M
    J Biol Chem; 2020 May; 295(20):6785-6797. PubMed ID: 32284326
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination Treatment With Remdesivir and Ivermectin Exerts Highly Synergistic and Potent Antiviral Activity Against Murine Coronavirus Infection.
    Tan YL; Tan KSW; Chu JJH; Chow VT
    Front Cell Infect Microbiol; 2021; 11():700502. PubMed ID: 34395311
    [TBL] [Abstract][Full Text] [Related]  

  • 37. COVID-19 updates: Remdesivir (Veklury) in high-risk outpatients with COVID-19.
    Med Lett Drugs Ther; 2022 Feb; 64(1644):31-32. PubMed ID: 35171898
    [No Abstract]   [Full Text] [Related]  

  • 38. Antiviral efficacy of favipiravir against Zika and SARS-CoV-2 viruses in non-human primates.
    Marlin R; Desjardins D; Contreras V; Lingas G; Solas C; Roques P; Naninck T; Pascal Q; Behillil S; Maisonnasse P; Lemaitre J; Kahlaoui N; Delache B; Pizzorno A; Nougairede A; Ludot C; Terrier O; Dereuddre-Bosquet N; Relouzat F; Chapon C; Ho Tsong Fang R; van der Werf S; Rosa Calatrava M; Malvy D; de Lamballerie X; Guedj J; Le Grand R
    Nat Commun; 2022 Aug; 13(1):5108. PubMed ID: 36042198
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment options for COVID-19: The reality and challenges.
    Jean SS; Lee PI; Hsueh PR
    J Microbiol Immunol Infect; 2020 Jun; 53(3):436-443. PubMed ID: 32307245
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Remdesivir: A beacon of hope from Ebola virus disease to COVID-19.
    Nili A; Farbod A; Neishabouri A; Mozafarihashjin M; Tavakolpour S; Mahmoudi H
    Rev Med Virol; 2020 Nov; 30(6):1-13. PubMed ID: 33210457
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.